Advertisement
Screener

NEUMORA THERAPEUTICS, INC. (NMRA) Auditor

NEUMORA THERAPEUTICS, INC. Auditor

The independent registered public accounting firm that signed the audit report in each annual report on Form 10-K, newest first. PCAOB firm ID and the internal-control attestation are as tagged on the cover from fiscal 2021; earlier rows come from the signed report text.

  • 2026-03-30: Fiscal year end 2025-12-31; Auditor Ernst & Young LLP; PCAOB firm ID 42; Location San Jose, California.
  • 2025-03-03: Fiscal year end 2024-12-31; Auditor Ernst & Young; PCAOB firm ID 42; Location San Jose, California.
  • 2024-03-07: Fiscal year end 2023-12-31; Auditor Ernst & Young; PCAOB firm ID 42; Location San Jose.
FiledFiscal year endAuditorPCAOB firm IDLocationInternal-control attestation
2026-03-302025-12-31Ernst & Young LLP42San Jose, CaliforniaNo
2025-03-032024-12-31Ernst & Young42San Jose, CaliforniaYes
2024-03-072023-12-31Ernst & Young42San Jose

Similar stocks

Stock NameCountryMarket CapPE Ratio
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22